We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App





Machine Learning Model Uses Blood Tests to Predict Survival of Critically Ill COVID-19 Patients

By HospiMedica International staff writers
Posted on 20 Jan 2022

A single blood sample from a critically ill COVID-19 patient can be analyzed by a machine learning model which uses blood plasma proteins to predict survival, weeks before the outcome, according to a new study. More...

Scientists at the Charité-Universitätsmedizin Berlin (Berlin, Germany) have found that the levels of 14 proteins in the blood of critically ill COVID-19 patients are associated with survival. Healthcare systems around the world are struggling to accommodate high numbers of severely ill COVID-19 patients who need special medical attention, especially if they are identified as being at high risk. Clinically established risk assessments in intensive care medicine, such as the SOFA or APACHE II, show only limited reliability in predicting future disease outcomes for COVID-19.

In the new study, researchers studied the levels of 321 proteins in blood samples taken at 349 timepoints from 50 critically ill COVID-19 patients being treated in two independent health care centers in Germany and Austria. A machine learning approach was used to find associations between the measured proteins and patient survival. 15 of the patients in the cohort died; the average time from admission to death was 28 days. For patients who survived, the median time of hospitalization was 63 days.

The researchers pinpointed 14 proteins which, over time, changed in opposite directions for patients who survive compared to patients who do not survive on intensive care. The team then developed a machine learning model to predict survival based on a single time-point measurement of relevant proteins and tested the model on an independent validation cohort of 24 critically ill COVID-10 patients. The model demonstrated high predictive power on this cohort, correctly predicting the outcome for 18 of 19 patients who survived and five out of five patients who died.

The researchers concluded that blood protein tests, if validated in larger cohorts, may be useful in both identifying patients with the highest mortality risk, as well as for testing whether a given treatment changes the projected trajectory of an individual patient.

Related Links:
Charité-Universitätsmedizin Berlin 


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
Medical Examination & Procedure Light
Vega 80
Blood Pressure Monitor
Cuff Blood Pressure Monitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Surgical Techniques

view channel
Image Credit: MedUni Wien/Houdek

New Surgical Technique Enlarges Aortic Root for Larger Valve Implantation

When replacing a diseased aortic valve, a small aortic root can prevent surgeons from implanting a prosthesis large enough for the patient’s body size. This can lead to patient-prosthesis mismatch, causing... Read more

Patient Care

view channel
Image Credit: Adobe Stock

AI Platform Personalizes Support Between Visits for Cancer Survivors

Cancer survivors often manage persistent side effects after treatment, including fatigue, anxiety, uncertainty, symptoms, stress, and questions between appointments. Clinical teams need ways to maintain... Read more

Medical Imaging

view channel
Image: The tool analyzes 3D time-of-flight MR angiography to measure brain vessel length, radius, volume, branching, tortuosity, and other structural features. (Photo courtesy of University of Rochester Medical Center)

MRI Tool Analysis Identifies Vascular Differences in Cerebral Small Vessel Disease

Cerebral small vessel disease (CSVD) involves changes or damage to the brain’s small blood vessels and is associated with stroke and cognitive impairment. Magnetic resonance imaging (MRI) can show cerebral... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: The proposed acquisition would add NeoCast, an investigational next-generation liquid embolic technology for chronic subdural hematoma (cSDH), to Terumo Neuro’s neurovascular portfolio. (Photo courtesy of Arsenal Medical)

Terumo Neuro Acquisition Advances Liquid Embolic Technology for Chronic Subdural Hematoma

Terumo Neuro (Aliso Viejo, CA, USA) signed an agreement to acquire Arsenal Medical Inc. (Waltham, MA, USA), a privately held, clinical-stage biomaterials company. The proposed acquisition would add NeoCast,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.